Key Quantitative Figures

Standalone Financial Results (Quarter Ended June 30, 2026 vs. June 30, 2025)

  • Revenue from operations: ₹186.08 crore (vs. ₹153.58 crore in Q4 FY26 and ₹172.70 crore in Q1 FY26)
  • Total Income: ₹193.71 crore
  • Profit before exceptional items and tax: ₹326.63 lakh
  • Exceptional Items: ₹23.58 lakh (balances written back/written off net)
  • Profit after tax: ₹2,444.40 lakh (₹24.44 crore)
  • Basic EPS: ₹2.81 (not annualized)
  • EBITDA: ₹33.32 crore (as per Note 1)

Consolidated Financial Results (Quarter Ended June 30, 2026)

  • Net Profit for the period after tax & exceptional items: ₹2,468.41 lakh
  • Total Comprehensive Income for the Period: ₹2,476.64 lakh

Land Sale Transaction

  • Land Area: 40 Bighas (approximately 10 acres)
  • Location: Village Behra, Derabassi, Punjab
  • Total Consideration: ₹17.50 crore
  • Transaction Timeline: To be completed over 9 months

Dates of Action

  • Board Meeting Date: 10th August, 2026
  • Agreement Date for Land Sale: 10th August, 2026
  • Financial Results Period: Quarter ended June 30, 2026

Parties Involved

  • Statutory Auditors: Rattan Kaur & Associates (CA Rattan Kaur)
  • Land Buyer: Nitin Jindal & Others
  • Subsidiaries Included: Fortune (India) Constructions Ltd, MJM Remedies Private Limited, Ind Swift Laboratories Inc. USA, ISLL Middle East LLC-FZ, Ind-Swift India Ltd (Kenya)
  • Joint Ventures Included: Indis Healthcare LLP, Capital Strikers LLP

Purpose or Rationale

  • The land was purchased earlier (disclosed to exchanges on 1st October 2024 and 12th December 2024) for setting up a manufacturing facility but was found unsuitable for setting up the Finished dosages facility as per applicable International regulatory/registration requirements.
  • The transaction does not constitute a related party transaction and is not part of any Scheme of Arrangement.

Financial Impact

  • The land sale will generate cash inflow of ₹17.50 crore over 9 months.
  • The transaction pertains to sale of a non-operational land parcel and does not relate to sale/disposal of any operational undertaking.

Capital Structure

  • Paid-up Equity Share Capital: ₹8,683.66 lakh (Face Value of ₹10 per share)
  • Reserves excluding revaluation reserves: ₹137,069.72 lakh (standalone)

Additional Information

  • The company is exclusively in the Pharmaceutical Business segment.
  • During the quarter, the company did not issue any Non-Convertible Debt Securities.
  • The previous period figures have been re-grouped and re-classified wherever necessary.
  • No adjustment has been made in respect of Deferred Taxes as per Ind-AS 12, as the same would be provided at year end.
  • The company has invested available surplus funds in various investment avenues monitored by an Investment Committee.
  • The financial results have been reviewed by the Audit Committee and approved by the Board of Directors.
  • The reports of the statutory auditors are unqualified.